Log in to save to my catalogue

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BRE...

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BRE...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751227777

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

About this item

Full title

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2012-11, Vol.13 (11), p.1087-1095

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks. We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain. Methods We undertook a multicentre, open-label, phase 2 trial in 24 centres in six...

Alternative Titles

Full title

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_1751227777

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1751227777

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(12)70431-X

How to access this item